Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 15/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | ACACA | Q13085 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3907842 | 0.93 | DPP4 (0.43) | DPP4PDPK1CYP3A4SCN9ASCN10A | |
| SCHEMBL3897759 | 0.92 | DPP4 (0.45) | DPP4ACACBACACAGRM2 | |
| SCHEMBL3902177 | 0.89 | DPP4 (0.57) | DPP4ACACBACACA | |
| SCHEMBL3896982 | 0.86 | DPP4 (0.66) | DPP4 | |
| SCHEMBL3894202 | 0.85 | DPP4 (0.43) | DPP4GRM2BRD4 | |
| SCHEMBL5455725 | 0.83 | DPP4 (0.45) | DPP4CYP3A4SCN9ASCN10A | |
| SCHEMBL3896466 | 0.82 | DPP4 (0.55) | DPP4 | |
| SCHEMBL3892661 | 0.81 | DPP4 (0.60) | DPP4 | |
| SCHEMBL3902192 | 0.79 | DPP4 (0.57) | DPP4 | |
| SCHEMBL5455502 | 0.78 | BDKRB1 (0.37) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547710-B2 | Fused heterocyclic compounds as peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-16 | — | — | US | disclosed |
| EP-1527049-B1 | FUSED HETEROCYCLIC COMPOUNDS AS PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-20060135530-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135530-A1 | Fused heterocyclic compounds | NR4A3, DPP3, INSR | DPP4 13/4885ACACB 3861/4885ACACA 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.